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2ABSTRACT (250 words)
Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major
public health threat. We have assessed the impact of the recently introduced national opt-
out policy on the current status of HCV testing in 14 prisons in the East Midlands (UK). We
analysed testing rates pre- and post-introduction of opt-out testing, together with face-to-
face interviews with prison healthcare and management staff in each prison.
In the year pre-opt-out, 1,972 people in prison (PIP) were tested, compared to 3440 in the
year following opt-out. From July 2016 – June 2017, 2706 people were tested, representing
13.5% of all prison entrants (median 16.6%, range 7.6% to 40.7%). Factors correlating with
testing rates were: pre-admission location of the PIP (another prison or the community, OR
2.2, 95% CI 1.9-2.3, p<0.001); whether the PIP could access healthcare independently of
prison officers (OR 1.7, 95% CI 1.5-1.8, p<0.001); an absence of out-reach services for HCV
treatment (OR 1.3, 95% CI 1.2-1.5, p<0.001), whether >50% of PIP reported ease of access to
a nurse (OR 2.0, 95% CI 1.8-2.2, p<0.001), and whether prison healthcare was supplied by
private or NHS providers (OR 1.3, 95% CI 1.2-1.5, p<0.001).
Testing rates remained far below the minimum national opt-out target of 50%. Inadequacy
of healthcare facilities and constraints imposed by adherence to prison regimens were cited
by healthcare and management staff at all prisons. Without radical change, the prison
estate may be intrinsically incapable of supporting NHSE to deliver the HCV elimination
strategy.
Key words: Chronic viral hepatitis; prisons; diagnostic virology; hepatitis C
3The campaign to eliminate hepatitis C virus (HCV) as a major public health threat by 2030
was established by the World Health Organisation in 20161 and given an accelerated target
of 2025 in the UK this year.2 The success of this campaign will depend on a comprehensive
and efficient testing process for the diagnosis of HCV in high risk groups and engagement of
infected individuals with viral eradication therapy. The prison population has a higher
prevalence of HCV infection than the general community due to the proportion of people in
prison (PIP) sentenced for crimes related to the use or distribution of drugs. In support of
this, a Health and Justice Report3 found that during 2014 seropositivity in prisons in the
England and Wales estate was 1.5% for hepatitis B virus (HBV), 8% for HCV and 0.6% for
human immunodeficiency virus (HIV) and a recent review estimated that 15.4% of PIP in
Europe are infected in contrast to a prevalence of 0.5% in the general population.4 Further,
in addition to the on-going high seroprevalence of HCV, injecting networks in prisons are
commonplace and provide an important driver of viral propagation.5,6 For example, whilst a
Scottish study identified a low incidence of HCV infection amongst all individuals in prison
who admitted ever injecting drugs, it estimated a much higher incidence (25.8 – 33.8%)
amongst those injecting during their current sentence.7 High rates of testing PIP for HCV
infection will therefore be a crucial determinant of the outcome of any elimination strategy.
Despite this background need, only 7.8% of (16,309/208,552) individuals entering prisons in
2013 were tested for blood borne viruses (BBV).8 This very low rate led to a joint
commissioning agreement between the National Offender Management Service, NHS
England and Public Health England that proposed an opt-out testing approach for BBVs,
based on the hypothesis that this would increase rates of test upake.9 An opt-out approach
requires testing to be embedded in routine care with the option to ‘opt-out’, in contrast to
an opt-in approach where patients are asked if they would like to have a test.10The joint
commissioning agreement stated that from April 2014 all PIP were to be tested near
reception into prison or at other time points, unless they specifically declined,9 with a target
to test 50-75% of those admitted.11 In view of the major importance of achieving these
targets for the ultimate success of the national HCV elimination strategy, and in responding
to impending increases in NHSE national targets for HCV treatment, we set out to evaluate
the impact of opt-out testing on the rates of test uptake in 14 prisons in the East Midlands
geographical region, as defined by the NHS commissioning board12 and to identify factors
contributing to the success or failure of this policy.
Methods
This report describes the first quantitative stage of a mixed methods sequential explanatory
study conducted within a realist evaluation methodology. The qualitative interviews and the
overall realist evaluation will be published separately. Data on the total numbers of HCV
tests performed on PIP at each of the East Midlands prisons was obtained. Numbers of dried
blood spot (DBS) tests received and tested were provided by the single regional
4microbiology department undertaking all the assays. This data has been received monthly
by the research team since August 2014 with the number of anti-HCV positive test results
being reported from October 2015. Data on the number of venous samples tested for anti-
HCV in the 12 month period before and after each establishment introduced the opt-out
policy was requested from the eight different laboratories that provide this service to the
prisons.
The numbers of PIP entering each prison per month, and the location from which they were
admitted (e.g. from the courts or transferred from another establishment) were received via
a Freedom of Information request to the Ministry of Justice. These data allowed
determination of the denominator population of people entering prison who should have
been tested for BBVs between January 2015 and July 2017. The PIP survey responses
regarding access to healthcare reported by Her Majesty’s Inspectorate of Prisons (HMIP)13
published by the end of 2017 were also reviewed.
Field visits to all East Midlands prisons were undertaken between January and March 2016
to meet key stakeholders in order to clarify, at each institution: the process whereby new
arrivals were dealt with by the healthcare team; which personnel were responsible for
organising blood-borne virus testing (BBV), and the method(s) of sampling; the timing and
location of BBV testing; the standard operating procedure (if present) for offering BBV
testing; how PIP were able to access the prison healthcare facility; the date of
commencement of DBS testing; and any perceived difficulties in achieving testing of PIP for
BBV. Interviews were conducted with the head of healthcare (n = 4, one of whom managed
2 prisons), the deputy head of healthcare (n = 2), the primary healthcare matron (n = 2, one
of whom was matron for 3 prisons), a senior healthcare nurse (n = 2) and a blood-borne
virus lead nurse (n = 1). This contextualised the delivery of healthcare in which the opt-out
approach to testing was situated.
Ethical approval was not believed to be required or sought for any of the above activities.
Data Analysis
Binomial logistic regression using SPSS V24 was undertaken to describe the relationships
between the percentages of people tested (dichotomous dependent variable) and the
following explanatory categorical variables: the PIP’s previous location prior to admission,
the location of testing within the prison, the requirement for a prison officer escort to
attend an appointment in healthcare, the availability of an out-reach HCV treatment service,
the ease of seeing a prison nurse within each prison, and whether the prison healthcare
service was from private or NHS providers.
5Results
Policy implementation
In the East Midlands, the opt-out policy was implemented at staggered times in the 14
prisons between August 2014 and July 2016. In addition, Public Health England (PHE)
contemporaneously commissioned the use of DBS samples within prisons as the first line
test to facilitate implementation of opt-out testing in the East Midlands. DBS tests are an
advantageous tool for BBV testing in people who inject drugs (PWID) who frequently have
damaged veins due to long term injecting,14 so this method was anticipated to encourage
PIP to engage in the testing process. The date of opt-out policy commencement in each
prison was therefore taken as dating from the first DBS sample referred for testing from
that prison (see Table 1).
Pre and post opt-out testing rates
The numbers of PIP undergoing testing for HCV in 14 prisons in the 12 months before and
after the introduction of the opt-out policy in each prison is shown in Table 2 and Figure 1.
Prison number 5, a category D open establishment, had not sent any DBS test requests so a
surrogate opt-out introduction date was chosen in keeping with the PHE 2nd pathfinder
phase in which this prison was included.15 Overall, in the 12 month pre-opt-out policy
period, 1,972 PIP were tested using venous samples. In the 12 month period after
introduction of the opt-out policy, 3,440 venous and DBS samples were tested, out of a
combined operational capacity in the 14 prisons of 9,539. Testing rates increased in ten
establishments, and decreased in four. The range of the change in numbers tested was -52
to 533.
Analysis of factors associated with testing rates
(i) Operational features of prison healthcare
Prison healthcare in the UK is provided by either the NHS or a private organisation
depending on local commissioning arrangements, with the aim of medical and nursing care
providing the equivalent of primary healthcare. When entering a prison, it is stipulated by a
mandatory Prison Service Order16 that PIP should have an initial first reception health check
which serves to triage immediate health needs, followed by a second reception health check
within the first week that comprises a more comprehensive assessment of health and
disability. These reception assessments are conducted by either general or mental health
registered nurses and documented in an electronic template in SystmOne, the national
clinical IT system. This template requires boxes labelled “Hepatitis B, C and HIV screening
offered” to be ticked by the clinician. The PIP’s response dictates whether BBV testing takes
place. Analysis of results from the 14 prisons found considerable heterogeneity on the
timing and location of tests undertaken for blood borne viruses (BBV). Some establishments
undertake the BBV test at either of the first or second appointments, whilst others arrange
6to see the PIP who have agreed to be tested during a separate BBV clinic (Table 1)
depending on the time and space available. For example, in prison number 2 the monthly
intake of PIP is approximately 500, which prohibits the routine second reception check being
offered to all new arrivals due to insufficient nurses and clinic space, so a more
comprehensive combined assessment is undertaken at the initial reception. Prison number
1, with an intake solely from other prisons, also routinely combines the two health-checks
when the PIP arrive, but cannot undertake testing at that time due to insufficient room
space and nursing availability, so additional blood test clinic appointments are arranged.
Staff from all establishments reported that maintaining the prison’s daily regime, or
timetable, took precedence over any routine healthcare activity and that clinics could not
overrun because the prison officers simply collect the PIP to return them to the location
dictated by the prison regime. Furthermore, any incidents of violence or disruption,
particularly episodes of concerted indiscipline, require additional prison officers to attend
the location. This results in other PIP being required to stay where they are because there
are no security staff to oversee their movement from one department to another, e.g. to
attend an appointment at the healthcare department.
In half of the prisons the PIP were permitted to walk to the healthcare department
unaccompanied by a prison officer at designated times of the day if they had an
appointment. The majority of testing took place in the healthcare department but three
prisons had clinic rooms in the prisoner accommodation (wings) and sometimes undertook
testing there too. BBV testing was undertaken by both registered nurses and healthcare
assistants and in one establishment by the substance misuse practitioners. Treatment for
HCV via an out-reach model was available in eight prisons during the time frame evaluated,
so those staff would have regular contact from hospital hepatitis specialist nurses.
Staff from all of the prisons described inadequate resources for the high volume testing that
an opt-out policy would necessitate, for example insufficient nurse or prison officer time,
inadequate clinic and waiting room space and limited time within the prison regime to see
all prisoners and discuss BBV testing. Notably, there is a Prison Service Instruction17 which
mandates that people entering prisons are processed in the shortest possible time because
the reception procedure can cause stress. For example, in prison number 1 there is an
internal prison “bus to bed” target of less than 2 hours and prison number 2 aims to have
PIP in their cells within an hour of their arrival.
Discussions with senior nurses and heads of healthcare at all locations confirmed that there
is no nationally or locally established standardised wording to present the opt-out approach
to testing to the PIP. Accordingly, whilst the notion of opt-out in general was understood,
there was a lack of clarity and consistency in accurately presenting the opt-out policy for
BBV tests to PIP. For example, at one establishment a senior nurse would go onto the prison
wings at weekends and ask “anyone not yet had a finger-prick test for hep and HIV?” and
7carry out DBS forthwith, in contrast to another prison where the PIP were simply asked on
arrival “do you want hep jabs and testing?”.
(ii) Other factors
By 1st July 2016 all prisons except one (prison 5) had commenced using DBS tests, as
commissioned locally for implementation of the opt-out policy, so this date was selected as
the starting point to further analyse opt-out implementation during a consistent time frame
for all sites. Data retrieved from the Ministry of Justice showed that overall, between 1st
July 2016 and 30th June 2017, 56.3% (11,312/20,075) of people who entered an East
Midlands prison came from another prison, and 42.8% (8,589/20,075) were admitted from a
community location, either directly from the courts (6,907, 35%) or by recall due to
breaching the terms of their licence release (1,682, 8%, see Table 3). During this period
2,706 people were tested, representing 13.5% of all who entered an East Midlands prison,
with a range across all prisons of 7.6% - 40.7%, and a median of 16.6% (see Table 4). 1,643
of those were tested using DBS and 1,063 via standard venepuncture. The overall rate of
anti-HCV positive results could not be calculated as this information from venous blood
samples was not available from all participating laboratories, but of the DBS tests, the anti-
HCV positivity rate was 9.3% (152/1,643), with a between-prison range of 0% to 23% and a
median of 3.5%.
Five factors were shown to correlate with prison testing rates (Table 5): testing rates were
higher if the main prison intake was from other prisons rather than the community (OR 2.2,
95% CI 1.9-to 2.3, p<0.001); where the PIP could walk to their healthcare appointment
independent of a prison officer (OR 1.7, 95% CI 1.5-to 1.8, p<0.001); where hepatitis C
treatment was provided at the hospital rather than via an out-reach service (OR 1.3, 95% CI
1.2-1.5, p<0.001), where over 50% of PIP reported it was easy to see a nurse (OR 2.0, 95%
CI 1.8-2.2, p<0.001), and where prison healthcare was private, rather than NHS providers
(OR 1.3, 95% CI 1.2-1.5, p<0.001). The location of testing within the prison i.e. a room near
the accommodation wing or in the healthcare department was not shown to correlate with
testing rates (OR 1.1, 95% CI 0.99 – 1.2, p<.063). Of the DBS samples collected the anti-HCV
positivity rate was 4-fold greater in prisons where the largest intake was from the
community, rather than from another prison (OR 3.9, 95% CI 2.7 – 5.6, p < .001).
Discussion
The introduction of opt-out testing across the East Midlands prison estate resulted in an
increase in the number of anti-HCV tests performed from 1972 to 3440 in the 12 months
pre- and post- operationalisation of the policy in each prison (Table 2, Figure 1). Using a
time-frame when opt-out testing had been introduced across all 14 prisons, and where
Ministry of Justice data on the number of people entering/leaving each prison was available
8(July 2016 to June 2017), 2706 tests were performed, out of a population of 20075
admissions across the estate (Table 4), giving a crude rate of 13.5%. This outcome is very far
below the Health and Justice Indicators of Performance lower testing threshold of 50% and
entirely inconsistent with achieving WHO targets.11
There are a number of unavoidable constraints on our data. Most importantly, there are
systematic difficulties in defining both the denominator (the total population that ought to
have been tested) and the numerator (number of PIP tested) used for calculating testing
rates. Whilst this is the first study, to the authors’ knowledge, to incorporate novel Ministry
of Justice data detailing the numbers of people entering prisons over time, some individuals
may have entered more than one prison in the study period, leading to an over-estimate of
the denominator. For the numerator, it cannot be assumed that the tests recorded were, in
fact, limited to those who entered the prison estate, as PIP already within the estate who
did not move prisons within the study timeframe may also have contributed to the test
numbers. It is also likely that some of the DBS samples were duplicates from the same
individual, especially for those PIP moving between prisons, and similarly, that some venous
samples were sent from PIP already tested by DBS, in order to confirm positive DBS test
results. We are unable to quantify this without reference to individualised patient data, but
given that the HCV positivity rates from venous samples in 5 prisons were in excess of 20%
(see Table 4), we believe the combined total of DBS plus venous samples will, in fact, be
greater than the true number of PIP tested. Our figure of 13.5% PIP tested (2,706 by either
DBS or VBT of an intake of 20,075 entrants) is therefore the best calculation we can perform
on the available data, but we believe this likely to be an overestimate. There is an evident
need for more accurate data relating to the numbers of individuals tested (as opposed to
the numbers of tests performed) and the true denominator against which to compare the
numbers tested.
A greater understanding of the factors which impact on testing may inform changes within
individual prison services. Category B remand prisons, with the highest rates of admission
from the community, had the lowest rates of testing. These prisons tend to have a shorter
length of stay (10 weeks for HMP Nottingham) and much higher turnover of PIPs than
prisons accommodating sentenced PIP (Table 3). Low rates of testing in this environment
risk failure to identify HCV infection in high risk groups who are then returned to the
community and deprived of the chance to receive anti-viral therapy in a relatively stable
prison environment. Remand prisons are therefore a focus for quality improvement
initiatives. The importance of ease of access to healthcare, identified in this context as the
ability to attend appointments unescorted and the perception of easy access to nurse
support, is consonant with the importance of minimising structural barriers to accessing
care in other settings.18,19 While prison regimens will have to take precedence, improving
access to healthcare may nonetheless be an achievable target.
9The observations that out-reach services impacted negatively on testing rates (which is
somewhat counter intuitive), and that undertaking HCV testing on the prison wings may
increase uptake (this did not quite achieve statistical significance, p = 0.063) will be explored
in a future qualitative publication following interviews with PIP. The former is likely to
reflect the established importance of confidentiality within the prison system.6,20
Attendance at a clinic known to be specifically set up for individuals at risk of HCV infection
may lead to social rejection by observant PIP making assumptions about risk behaviours or
HCV status, thereby contributing to stigma and creating a barrier to PIP accessing care
pathways. Preference for testing on wings most likely reflects a reluctance of individual PIP
to leave their wing for a number of reasons, including competing time-restricted activities
(e.g. preference for receipt of items purchased in the canteen rather than spending time
going to healthcare) and fear of violence if a PIP has drug debts or is a sex offender in a non-
specialist prison. A consequence of this finding would be to recommend that testing should
be available at different locations and time points in the prisons.
We also identified serious misinterpretations of what an opt out policy actually means, so it
is possible that improved training and more appropriate introduction of a true opt-out
policy may result in some increase in testing numbers. We suggest that the consistent use of
a simple phrase such as "We test everyone who comes into prison for hepatitis C (which is
completely curable), hepatitis B and HIV (which are treatable), is that OK with you?” may
help increase uptake. We note, however, that all management and healthcare staff
interviewed from each of the 14 prisons described inadequate resources for the high
volume testing required by an opt-out policy, for example insufficient nurse or prison officer
time, inadequate clinic and waiting room space and limited time within the prison regime to
see all prisoners and discuss BBV testing. Current prison infrastructure is therefore likely to
be the principle rate determining factor.
We have been unable to locate any directly comparable studies in the literature. However,
HCV testing rates increased in a North-East prison from 2.3% in 2014/15 to 35% in 2016/17
following the introduction of the opt-out approach and concurrent DBS test method. 21 The
key features to note were a combined hospital, prison and commissioning Task and Finish
group who introduced a robust test and treat pathway, and nurses adopting a positive
approach to positioning BBV testing as a routine component of entering prison. There are
further examples of the opt-out approach being effective in different clinical contexts. NHS
England cited increased uptake of testing for blood borne viruses in some genitourinary
clinics and emergency departments as evidence for adopting this approach in prisons.8
However these community contexts contrast sharply with a prison environment where
multiple environmental, psycho-social and cultural differences impact on all stages of the
process. A wider corpus of evidence is available from the US prison system. Significant
increases in testing for HIV in that system following introduction of an opt-out policy have
been reported, with a final figure in all cases exceeding 75%. 22–24 All of those prisons,
however, also tested routinely for syphilis, so PIP were opting out of a blood test on a
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sample collected for a different clinical purpose. Three further studies report that opt-out
testing for HIV increased from 7% to 73% in a female prison25 from 20% to 53% in a male
prison 26and from 70% to 98% in a mixed prison 27when tested the day after arrival using
rapid point of care oral tests. These studies suggest that moving towards a test which does
not require a blood sample and/or provides a same day result may impact on uptake of
testing offered as part of an opt-out policy.
In summary, we have conducted an evaluation of HCV testing in a large UK Prison Estate.
Whilst this evaluation was conducted in a single geographical region, the 14 prisons in the
East Midlands vary in security category, size and purpose, and are therefore likely to provide
a representative sample of the challenges of conducting efficient testing for HCV in UK
prisons. Further, the different data types gathered in our study collectively strengthen the
evaluation by highlighting factors which were predictive of uptake and supplying a broader
insight into the issues at stake beyond simply the test uptake figures. Prisons present an
apparently opportune context for the delivery of healthcare, and a more ordered
environment for the delivery of treatment than many community settings. They are,
however, principally establishments that remove individuals’ liberty both as punishment
and for public protection, so the maintenance of prison security regimens will always be the
priority. The evidence presented here clearly illustrates that rates of anti-HCV testing in a
representative prison estate in the East Midlands following the introduction of opt-out
testing remain far below national targets. Our study indicates that, despite models of
successful interventions in individual prisons (see Table 2 and reference 21), urgent
systematic change is required to create simple and transferable models of care and
normalize the concept of HCV testing in prisons. Further, our multiple data sources and
contextual information from stakeholders lead us to conclude that, while an increased
application of the opt-out policy may make an incremental change, the major factors
operating in this failure relate principally to the infrastructure within prison healthcare
facilities, which in most prisons are not equipped in terms of staff or space to deal with the
increased workload that a 50% testing target would engender, and the low priority of BBV
testing within the overall prison regimen. As the prison estate is a critical demographic in
the UK drive to eliminate HCV as a major public health threat by 20252 our findings have
major implications for the success of this policy. We therefore suggest that further dialogue
between the National Offender Management Service, NHS England and Public Health
England will be required to take account of our findings and ensure the ultimate success of
strategies to increase rates of testing for HCV in UK prisons.
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Table 1. Operational features of the 14 East Midlands prisons
Prison Prison
security
category1
Opera-
tional
capacity2
Timing of BBV testing Source of
largest
intake of
prisoners
Health-
care
provider
Escorted by
Prison Officer
or unescorted
to health care
department3
Testing
on
wings
In-reach
HCV
treatment
available
% reporting
easy or very
easy to see
prison
Nurse2
1 C 1088 BBV test clinic Other prison Both yes yes 35
2 B local 1048 2nd Reception Community PO escort no yes 25
3 C 841 BBV test clinic Other prison PO escort no no 64
4 B training 915 2nd Reception and Well Man
clinic
Other prison PO escort no yes 41
5 D 581 Rarely test Other prison Unescorted no no 53
6 Female closed 343 BBV test clinic, on wings Community Unescorted yes yes 33
7 B local 729 Combined 1st and 2nd
reception
Community PO escort no no 31
8 D 420 2nd Reception Other prison Unescorted no no 81
9 C 681 2nd Reception Other prison PO escort no yes 48
10 B local 325 BBV test clinic Community PO escort no yes 48
11 Young
offender
515 1st or 2nd Reception Other prison Unescorted no yes 53
12 B training 697 2nd Reception and BBV clinic Other prison Unescorted no yes 67
13 C 734 2nd Reception and BBV clinic Other prison Unescorted yes no 42
14 B 622 2nd Reception Other prison unescorted no no 39
(1) Prisons are assigned a security category according to the degree of protection they provide to reduce the risk of escape posed by the PIP housed in each establishment The PIP are assigned a category according
to the lowest level of security required to safely retain them in custody whilst simultaneously protecting the public by preventing the PIP from escaping. Male and female prisons have different categories: Category B
-Men for whom the very highest conditions of security are not necessary but for whom escape must be made very difficult; Category C - Men who cannot be trusted in open conditions but who do not have the
resources, will or determination to attempt escape; Category D - Men who can reasonably be trusted in Open conditions; Young Offender Institution - Young men aged 18 to 21 years, either Open or Closed
conditions; Female Closed - Women who do not necessarily pose such a risk to the public that would warrant a place in a high security establishment but who are too high risk for an open prison.
(2) Operational capacity and PIP perception of ease of seeing a nurse are taken from Her Majesty’s Inspectorate of Prisons reports.
(3) Some prisons permit PIP to walk to the healthcare department unaccompanied, others require prison officers to collect PIP from the wings and take them. This can be dependent on the prisons security category
or the PIPs behaviour.
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Table 2. Details of anti-HCV testing per prison during 12 months pre and post introduction of the opt-out policy.
Prison Number of
VB samples
sent 12
months
before DBS
began
VB samples
anti-HCV
positive:
n (%)
Date first
DBS
Number
of DBS
samples
sent in
first 12
months
DBS anti-
HCV
positive:
n (%)
Number of
VB
samples
sent in
first 12
months of
DBS use
VB
samples
anti-HCV
positive:
n (%)
Number of
VB and DBS
tests
combined
in first 12
months of
opt-out
policy
Difference in
number of tests
(VB vs DBS and
VB combined) in
first 12 months
after
introduction of
opt-out policy
1 250 36 (14.4) Mar-16 248 36 (14.5) 85 32 (37.6) 333 83
2 540 84 (15.5) Aug-14 281 notrecorded 375 51 (13.6) 656 116
3 92 4 (4.3) May-15 5 notrecorded 84 3 (3.6) 89 -3
4 226 28 (12.4) Jul-15 2 notrecorded 172 27 (15.7) 174 -52
5* 115 not recorded Jan-15 0 notrecorded 131
not
recorded 131 16
6 273 not recorded Feb-15 115 notrecorded 132
not
recorded 247 -26
7 273 49 (17.9) Feb-15 322 notrecorded 69 6 (8.7) 391 118
8 38 6 (15.8) Feb-15 281 notrecorded 12 3 (25) 293 255
9 0 0 Aug-14 125 notrecorded 1 1 126 126
10 22 14 (66.6) Jan-16 43 1 (2.3) 88 27 (30.7) 131 109
11 10 1 (10) Feb-15 526 notrecorded 17 2 (11.8) 543 533
12 41 9 (22) Jul-16 2 0 37 6 (16.2) 39 -2
13 40 not recorded Mar-16 163 7 (4.3) 19 notrecorded 182 142
14 52 not recorded Apr-16 102 0 3 notrecorded 105 53
TOTAL 1972 2215 1225 3440
* Young Offender Institution. Decommissioned April 2017.
VB = Venous Blood; DBS = Dried blood spot
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Table 3. Number of people entering each of the 14 East Midlands prisons from each location between 1st July 2016 and 30th June 20171
Location Type
Prison
number
Prison security
category
From other
prison
From
court
From
licence
recall
From
other
location(2)
Total
entering
prison
Operational
capacity
1 C 1,847 1 0 0 1,848 1088
2 B local 1,634 3,422 880 76 6,012 1048
3 C 436 2 0 2 440 841
4 B training 625 0 0 1 626 915
5 D open prison 980 0 0 1 981 581
6 Female closed 204 954 144 11 1,313 343
7 B local 755 1,505 387 46 2,693 729
8 D open prison 558 0 0 0 558 420
9 C 1,073 0 0 1 1,074 681
10 B local 724 774 224 28 1,750 325
11 YOI* 847 247 47 5 1,146 515
12 B training 221 0 0 3 224 697
13 C 1,108 0 0 0 1,108 734
14 B 300 2 0 0 302 622
All prisons 11,312 6,907 1,682 174 20,075 9,359
(1) A prisoner may be admitted to prison custody on more than one occasion during a quarter, and a prisoner may be admitted
on multiple occasions across different quarters. For example, a prisoner will be counted as being admitted to prison custody the
first time they enter prison custody for an offence committed, further if the prisoner is transferred to another prison within the
East Midlands, this will also be counted as an 'admission'.
(2) Other locations include high security hospitals and approved premises.
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Table 4. Anti-HCV Venous and DBS samples requested between 1st July 2016 and 30th June 2017
Prison n = tested with
dried blood
spot samples
n= anti-
HCV DBS
positive
results
% = anti-
HCV DBS
positive
results
n = tested
with venous
blood samples
n= anti-
HCV VBS
positive
results
% = anti-
HCV VBS
positive
results
n = total
tests
n = admissions to
prison July 2016
to June 2017
% prison
intake total
tested
1 185 24 13 86 45 52.3 271 1848 14.7
2 136 27 19.9 320 65 20.3 456 6012 7.6
3 1 0 0 110 1 0.9 111 440 25.2
4 0 0 0 181 18 9.9 181 626 29
5 0 0 0 109 n/a n/a 109 981 11.1
6 144 28 19.4 69 27 39.1 213 1313 16.2
7 245 37 15.1 75 8 10.7 320 2693 11.9
8 222 7 3.2 5 4 80 227 558 40.7
9 189 4 2.1 0 0 0 189 1074 17.6
10 123 12 9.8 29 14 48.3 151 1750 8.6
*11 215 8 3.7 15 8 53.3 231 1146 20.2
12 2 0 0 42 7 16.7 38 224 17
13 105 5 4.8 22 n/a n/a 127 1108 11.5
**14 76 0 0 n/a n/a n/a 76 302 0
TOTAL 1643 152 9.3 1063 197 18.5 2706 20075 13.5
*Establishment decommissioned April 2017
** Venous sample data was not supplied per month so unable to align with time frame. However from 01.04.16 to 31.03.17 they requested 3 tests
and between 01.04.17 to 31.10.17 they requested 4 tests.
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Table 5. Prison factors associated with venous and dried blood spot test uptake
Prison healthcare characteristic n= % OR (95% CI) p=
HCV tests undertaken where largest intake is from the community (n=4 prisons) 1,140/ 11,768 9.7
HCV tests undertaken where largest intake is from another prison (n=10) 1,560/ 8,307 18.8 2.2 (1.9-2.3) <.001
HCV tests undertaken when prison officer escort to healthcare required (n=6) 1,679/ 14,443 11.6
HCV tests undertaken when prison officer escort to healthcare not required (n=7) 1,021/ 5,632 18.1 1.7 ( 1.5-1.8) <.001
HCV tests undertaken on or close to prison wings (n=3) 611/ 4,269 14.3
HCV tests undertaken in central prison healthcare department (n=11) 2,089/15,806 13.2 1.1 (0.99 – 1.2) 0.063
HCV tests undertaken when in-reach anti-viral treatment available (n=8) 1,730/ 13,993 12.4
HCV tests undertaken when in-reach anti-viral treatment not available (n=6) 970/ 6,082 16 1.3 (1.2-1.5) <.001
HCV tests undertaken where HMIP* reported < 50% said it is easy to see nurse (n=9) 1,984/ 16,726 11.9
HCV tests undertaken where HMIP* reported > 50% said it is easy to see nurse (n=5) 716/ 3,349 21.4 2 (1.8 - 2.2) <.001
HCV tests undertaken in prisons where healthcare provider is NHS (n=9) 2002/15965 12.5
HCV tests undertaken in prisons where healthcare provider is private (n=4) 587/3670 16.0 1.3 (1.2-1.5) <.001
* Her Majesty’s Inspectorate of Prison
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Figure legend:
Figure 1. Number of HCV tests requested in 14 prisons during 12 months before (venous
blood samples) and after (DBS and venous samples combined) the introduction of the opt-
out policy.

